Previous 10 | Next 10 |
home / stock / mrvl / mrvl articles
Marvell Technology, Inc. (NASDAQ: MRVL) shares are trading higher in Thursday's post-market session after the company reported third-quart...
Shares of semiconductor and chip stocks are trading lower on Tuesday. Weakness may be due to weak guidance from Analog Devices (NASDAQ: ADI). What...
Susquehanna analyst Christopher Rolland reiterated a Positive rating on Marvell Technology, Inc (NASDAQ: MRVL) with a price tar...
Marvell Tech (NASDAQ:MRVL) has outperformed the market over the past 10 years by 4.99% on an annualized basis producing an average annual return of...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Trade Desk, Inc. (NASDAQ: TTD) is an "expensive stock, but it is ...
NVIDIA Corp. (NASDAQ: NVDA) stock traded down nearly 5% on Tuesday afternoon following news the U.S. is implementing new restri...
Marvell Tech (NASDAQ:MRVL) has outperformed the market over the past 5 years by 15.2% on an annualized basis producing an average annual return of ...
Specialty-semiconductor stocks, Skyworks Solutions Inc. (NASDAQ:SWKS) and Qorvo, Inc. (NASDAQ:QRVO), have been downgraded by Ci...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Veeva Systems Inc. (NYSE: VEEV) is a buy, even though it’s a "h...
News, Short Squeeze, Breakout and More Instantly...
Marvell Technology Inc. Company Name:
MRVL Stock Symbol:
NASDAQ Market:
Marvell Technology Inc. Website:
Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to report that, further to its press releases of May 16, 2024 and June 21, 2024, it has ...
2024-07-15 18:00:00 ET Broadcom (NASDAQ: AVGO) and Marvell Technology (NASDAQ: MRVL) usually don't attract as much attention as higher-growth chipmakers like Nvidia (NASDAQ: NVDA) . But like Nvidia, both diversified chip specialists are benefiting from the rapid ...
Calgary, Alberta--(Newsfile Corp. - July 9, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to highlight the recently published paper "Neuronal A2A receptor exacerbate...